ng next generation sequencing

负责人：

关键词：

Next-generation sequencing;cell-free DNA;Melanoma;digital droplet PCR;pancreatic ductal adenocarcinoma;colorectal adenocarcinoma

DOI：

doi:10.5061/dryad.7pj51v0

摘要：

of cell-free DNA in clinical oncology. In this study, isolation of short cell-free DNA fragments is shown to enrich for tumor variants and improve correction of PCR

Data from: Quality of evidence considered by Health Canada in granting full market authorization to new drugs with a conditional approval

负责人：

关键词：

Health policy;Health Canada;regulation;Clinical Trials;postmarket;Confirmatory studies;methodology

DOI：

doi:10.5061/dryad.82jv0

摘要：

. The absence of blinding in the majority of RCTs may introduce bias in their results. The use of surrogate outcomes especially in oncology trials means tha

Data from: Are patients with cancer with sepsis and bacteraemia at a higher risk of mortality? A retrospective chart review of patients present

负责人：

关键词：

Shock;Emergency Department;mortality;sepsis;Cancer

DOI：

doi:10.5061/dryad.6qk05

摘要：

er in the setting of sepsis. Conclusions: This is the first study looking at an in-depth analysis of sepsis in the specific oncology population. Despite aggressive

Data from: Extent and cost of inappropriate use of tumour markers in patients with pulmonary disease: a multicentre retrospective study in Shanghai, China

负责人：

关键词：

inappropriate request;cost;tumor marker;pulmonary disease;overuse of medical services

DOI：

doi:10.5061/dryad.nb3r0

摘要：

. Setting: The respiratory, thoracic surgery, and oncology departments of three hospitals in Shanghai, from 2014 to 2015. Participants: Patients

Data from: Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry

负责人：

关键词：

Adverse events;Clinical Trials;Health & safety

DOI：

doi:10.5061/dryad.3t6sc

摘要：

eas (cardiovascular diseases, mental health and oncology). Multivariable logistic regression was used to evaluate factors associated with the us

Data from: Association between commercial funding of Canadian patient groups and their views about funding of medicines: an observational study

负责人：

关键词：

health technology assessment;Canada;patient organizations;public funding;2012-2018;conflict of interest;pharmaceutical companies

DOI：

doi:10.5061/dryad.th725q8

摘要：

t Canadian groups take about the products and conflicts of interest with the companies. Methods: The Common Drug Review (CDR) and panCanadian Oncology Drug